miscsubjectsAI governance
Evidence review

SS-31 (Elamipretide) for IBD: Mitochondrial Repair Pathways in Crohn's and Colitis Research

bundle · json · system map · manifest

Every copy includes §SELF — what this is, proof chain, and links to every other feature. No context required.

§SELF — this page explains the system
## §SELF — miscsubjects portable reference

**Principle:** Self-explaining payload — no external context required. This _self block describes what you are reading and where to look next.

**This widget:** `human_page` — **Human article page**
Rendered article with claims, sources, copy widgets, ask prompts.
- **article slug:** `ss-31-ibd`
- **contains:** rendered article, copy widgets, claims, sources, ask prompts
- **how to use:** Use Copy for LLM or Copy system map — both paste without context.
- **read:** https://miscsubjects.com/a/ss-31-ibd

### Logical proof (verify each step)
1. Articles are voxel graphs of tiered claims, not prose blobs. → https://miscsubjects.com/api/articles/constitution
2. Claims link to hash-chained sources via source_ids. → https://miscsubjects.com/api/articles/ss-31-ibd/sources
3. Ask reads topology; ingest/claim append to ledger. → https://miscsubjects.com/api/protocol
4. Models queue growth: populate → collaborate → repair → reflex. → https://miscsubjects.com/api/protocol/grow
5. Graph proves its own shape (reflex) and $/claim (yield). → https://miscsubjects.com/graph.html?layer=reflex
6. Full feature index + _explain on every API response. → https://miscsubjects.com/api/articles/system-map

### Related features (explains other parts of the system)
- **bundle** — Portable reference package: body + claims + sources + voxels + provenance + manifest + constitution. · https://miscsubjects.com/api/articles/ss-31-ibd/bundle?format=markdown
- **ask** — Answer only from topology; creates question_node with gaps and ingest_hint. · https://miscsubjects.com/api/articles/ss-31-ibd/prompts
- **topology** — Claims, sources, anecdotes, user reports, related embeds, question graph slice — for ask/ROUTER. · https://miscsubjects.com/api/articles/ss-31-ibd/topology

### Full index
- JSON: https://miscsubjects.com/api/articles/system-map
- Markdown: https://miscsubjects.com/api/articles/system-map?format=markdown

*Not medical advice. Tier-honest. Cite claim/source ids.*

What's breaking down if you have IBD (Crohn's / colitis)

The body is always doing two things at once: breaking down (degeneration) and building back (regeneration). A condition persists when breakdown outruns repair. Most drugs used for symptoms suppress a signal (pain, acid, anxiety, inflammation) without fixing the tissue that caused the signal. Peptides in this ledger are studied for repair pathways: new blood vessels, repair-cell migration, nerve regrowth, gut lining, neural connections. This article maps one compound through that frame — what it is, how it is proposed to work, what evidence exists, and what people report.

Why SS-31 (Elamipretide) might help you

  1. You are reading about IBD (Crohn's / colitis) — what breaks down matters before any compound name.
  2. Therefore for you: If that layer is part of your problem, SS-31 (Elamipretide) is discussed because it targets repair (tissue) — not because it masks pain.

How these fit together

Single-compound focus — if your condition profile includes a multi-peptide stack, siblings target other layers listed in the condition profile.

  • SS-31 (Elamipretide) → mitochondrial

What the evidence actually shows

This is a count of what is in this ledger — not a claim about all research worldwide.

  • Scientific sources catalogued (PubMed, trials, reviews): 3
  • Claims tagged human evidence: 2
  • Claims tagged preclinical (animal/lab): 1
  • Claims tagged anecdotal: 0
  • Reddit posts catalogued: 0
  • X posts catalogued: 0
  • Other anecdote sources (YouTube, Instagram, etc.): 0
  • Total sources in chain: 5

Logic: No social posts catalogued yet — we cannot report what people are saying on Reddit or X from this ledger.

Quantified confidence (this ledger): 0.36 / 1.00 — low–moderate — mostly preclinical

Formula: human claims×0.12 + preclinical×0.04 + anecdote×0.015 + studies (capped). This is not clinical certainty — it measures how much graded evidence is catalogued here.

What scientists say

Perturbed Mitochondrial Dynamics Is a Novel Feature of Colitis (source s1)

Links mitochondrial changes to DSS colitis model.

Evidence type: Published research.

Elamipretide: A Review of Its Structure, Mechanism of Action... (source s2)

Details cardiolipin binding and ROS reduction.

Evidence type: Published research.

Elamipretide (SS-31) improves mitochondrial dysfunction... (source s4)

Mouse study on inflammation and mitochondria; no IBD human data.

Evidence type: Tagged human evidence in this ledger — check sample size and design.

---

Not medical advice. Counts and quotes are from this article's hash-chained ledger. Anecdote = real reports, not proof. Animal studies ≠ human proof.

Explore this article's relationships

IBD / Crohn / colitis · condition map

Connected articles

Where this sits in the evidence graph. Open the full interactive map for the whole neighborhood.

Full map →
Evidence · 5 sources · swipe →chain fafb89ded98f · verify chain · provenance
Evidence ledger 5 · tier-ranked · API
humanlow confidence
No published human trials test SS-31 in IBD patients.
sources: s4
humanlow confidence
Elamipretide received FDA approval in 2025 for Barth syndrome.
sources: s5
preclinicallow confidence
DSS-induced colitis mouse models show SS-31 protects epithelial cells and lowers mucosal oxidative stress.
sources: s3
mechanisticlow confidence
Mitochondrial dysfunction contributes to epithelial barrier failure and oxidative stress in IBD tissue.
sources: s1
mechanisticlow confidence
SS-31 binds cardiolipin to stabilize mitochondrial membranes and reduce ROS production.
sources: s2
Model review1 contributions · 1 modelExpand the recursive review layer
1 / 1
grok/grok-4.3writer
redraft2026-06-29 23:53
SS-31 (Elamipretide) for IBD: Mitochondrial Repair Pathways in Crohn's and Colitis Research · 5 claims · 5 sources
inspect — what it was prompted & output
prompted with
(default writer prompt)

input: Write a data-first, evidence-graded article: Ss 31 for Ibd
Slug: ss-31-ibd
Audience: readers researching peptide evidence for this specific condition or drug cross.
Rules: label every claim tier (human|preclinical|anecdotal|mechanistic|speculative). Separate human trials from rat studies from Reddit/X anecdotes. No medical claims. Repair-vs-suppression framing. register: source_ledger.

ENRICHMENT BRIEF (binding section logic — one ## per compound):
{"voice":"enrichment","article_shape":"single_cross","condition":"IBD (Crohn's / colitis)","condition_key":"ibd-crohns-colitis","primary_peptide":"ss-31","peptides_in_scope":[{"id":"ss-31","name":"SS-31 (Elamipretide)"}],"drugs_in_scope":[],"weight_sensitive":false,"stimulant_context":false,"breaking_down":{"section_title":"What's breaking down
it output
{
  "slug": "ss-31-ibd",
  "title": "SS-31 (Elamipretide) for IBD: Mitochondrial Repair Pathways in Crohn's and Colitis Research",
  "body": "## What's breaking down if you have IBD (Crohn's / colitis)\n\nIBD involves ongoing inflammation in the gut lining. Epithelial cells in the intestine face repeated oxidative stress and energy shortfalls. Mitochondria inside those cells produce the ATP needed for barrier maintenance and repair. When mitochondria falter, reactive oxygen species rise, tight junctions loosen, and the barrier becomes more permeable. Immune cells then overreact to luminal contents, creating a cycle where breakdown outpaces repair. Mitochondrial dysfunction appears in both Crohn's and ulcerative colitis tissue samples. It contributes to cell death signals and slowed regeneration of the mucosa.\n\n## Why SS-31 (Elamipretide) might help you\n\nIf mitochondrial energy failure sits at one layer of your IBD picture, SS-31 targets that layer directly. The peptide binds cardiolipin in the inner mitochondrial membrane. This binding stabilizes the membrane structure. Stabilized membranes reduce electron leakage and lower reactive oxygen species output. Lower ROS means less damage to nearby proteins and DNA. Less damage allows epithelial cells to maintain ATP levels for repair processes. If the problem layer includes oxidative stress driving inflammation, the mitochondria
64a21c89a137e1ce
Machine verification: /api/articles/ss-31-ibd/contributions
Ask this article · 7 suggested prompts

Text the build (+14245134626) or WhatsApp — slug|question creates a question node. Paste evidence with ingest slug|q:NODE_ID|your paste.

What does the ledger say about this (human tier): "No published human trials test SS-31 in IBD patients."?
ask ss-31-ibd claim c4 · paste includes §SELF
What does the ledger say about this (human tier): "Elamipretide received FDA approval in 2025 for Barth syndrome."?
ask ss-31-ibd claim c5 · paste includes §SELF
What does the ledger say about this (preclinical tier): "DSS-induced colitis mouse models show SS-31 protects epithelial cells and lowers mucosal oxidative stress."?
ask ss-31-ibd claim c3 · paste includes §SELF
What does the ledger say about this (mechanistic tier): "Mitochondrial dysfunction contributes to epithelial barrier failure and oxidative stress in IBD tissue."?
ask ss-31-ibd claim c1 · paste includes §SELF
What does the ledger say about this (mechanistic tier): "SS-31 binds cardiolipin to stabilize mitochondrial membranes and reduce ROS production."?
ask ss-31-ibd claim c2 · paste includes §SELF
For my medical situation, what can you answer from your catalogue about SS-31 (Elamipretide) for IBD: Mitochondrial Repair Pathways in Crohn's and Colitis Research — and what would you need me to tell you first?
ask ss-31-ibd condition gaps · paste includes §SELF
What good and bad outcomes are documented for SS-31 (Elamipretide) for IBD: Mitochondrial Repair Pathways in Crohn's and Colitis Research (studies vs anecdotes)?
ask ss-31-ibd good bad experiences · paste includes §SELF
Add your experience or question
Think this article is wrong?
Call bullshit on CharlieOS →
Loading more articles…